相似文献
1
Emergence of a Streptococcus pneumoniae clinical isolate highly resistant to telithromycin and fluoroquinolones.
J Clin Microbiol. 2005 Nov;43(11):5800-3. doi: 10.1128/JCM.43.11.5800-5803.2005.
2
Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.
Antimicrob Agents Chemother. 2005 Jan;49(1):188-94. doi: 10.1128/AAC.49.1.188-194.2005.
3
Mutational analysis of reduced telithromycin susceptibility of Streptococcus pneumoniae isolated clinically in Japan.
FEMS Microbiol Lett. 2010 Jun;307(1):87-93. doi: 10.1111/j.1574-6968.2010.01962.x. Epub 2010 Mar 19.
4
Molecular epidemiology of fluoroquinolone resistance in invasive clinical isolates of Streptococcus pneumoniae in Seville.
Enferm Infecc Microbiol Clin. 2012 Apr;30(4):180-3. doi: 10.1016/j.eimc.2011.10.006. Epub 2012 Feb 24.
5
6
High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2007 Mar;51(3):1092-5. doi: 10.1128/AAC.01153-06. Epub 2007 Jan 8.
7
Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
J Antimicrob Chemother. 2007 Jun;59(6):1171-6. doi: 10.1093/jac/dkm089. Epub 2007 Apr 3.
8
Molecular characterization of the first telithromycin-resistant Streptococcus pneumoniae isolate in Germany.
Antimicrob Agents Chemother. 2005 Aug;49(8):3520-2. doi: 10.1128/AAC.49.8.3520-3522.2005.
9
Activity of telithromycin against erythromycin-susceptible and -resistant Streptococcus pneumoniae isolates from adults with invasive infections.
Int J Antimicrob Agents. 2004 Dec;24(6):616-8. doi: 10.1016/j.ijantimicag.2004.06.018.
10
Emergence and epidemiology of fluoroquinolone-resistant Streptococcus pneumoniae strains from Italy: report from the SENTRY Antimicrobial Surveillance Program (2001-2004).
Diagn Microbiol Infect Dis. 2006 Mar;54(3):157-64. doi: 10.1016/j.diagmicrobio.2005.08.012. Epub 2006 Jan 19.
引用本文的文献
1
The macrolide antibiotic renaissance.
Br J Pharmacol. 2017 Sep;174(18):2967-2983. doi: 10.1111/bph.13936. Epub 2017 Aug 10.
2
Resistance to Macrolide Antibiotics in Public Health Pathogens.
Cold Spring Harb Perspect Med. 2016 Oct 3;6(10):a025395. doi: 10.1101/cshperspect.a025395.
3
Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.
Clin Microbiol Rev. 2016 Jul;29(3):525-52. doi: 10.1128/CMR.00058-15.
4
A novel ketolide, RBx 14255, with activity against multidrug-resistant Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2014 Aug;58(8):4283-9. doi: 10.1128/AAC.01589-13. Epub 2014 Feb 18.
5
Telithromycin resistance in Streptococcus pneumoniae is conferred by a deletion in the leader sequence of erm(B) that increases rRNA methylation.
Antimicrob Agents Chemother. 2008 Feb;52(2):435-40. doi: 10.1128/AAC.01074-07. Epub 2007 Dec 3.
6
High-level telithromycin resistance in a clinical isolate of Streptococcus pneumoniae.
Antimicrob Agents Chemother. 2007 Mar;51(3):1092-5. doi: 10.1128/AAC.01153-06. Epub 2007 Jan 8.
7
Telithromycin-nonsusceptible clinical isolates of Streptococcus pneumoniae from Europe.
Antimicrob Agents Chemother. 2006 Nov;50(11):3897-900. doi: 10.1128/AAC.00057-06.
8
Streptococcus pneumoniae isolates resistant to telithromycin.
Antimicrob Agents Chemother. 2006 May;50(5):1855-8. doi: 10.1128/AAC.50.5.1855-1858.2006.
本文引用的文献
1
Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A beta-haemolytic streptococci in 2002-2003. Results of the multinational GRASP Surveillance Program.
Int J Antimicrob Agents. 2005 Feb;25(2):148-56. doi: 10.1016/j.ijantimicag.2004.09.016.
2
Influence of carbon dioxide on the MIC of telithromycin for Streptococcus pneumoniae: an in vitro-in vivo study.
Antimicrob Agents Chemother. 2005 Jan;49(1):464-6. doi: 10.1128/AAC.49.1.464-466.2005.
3
Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
J Antimicrob Chemother. 2004 Aug;54(2):515-23. doi: 10.1093/jac/dkh356. Epub 2004 Jul 21.
4
Activity of telithromycin against key pathogens associated with community-acquired respiratory tract infections.
J Infect. 2004 Aug;49(2):115-25. doi: 10.1016/j.jinf.2004.03.009.
5
Clinical efficacy of ketolides in the treatment of respiratory tract infections.
J Antimicrob Chemother. 2004 Jun;53(6):918-27. doi: 10.1093/jac/dkh169. Epub 2004 Apr 29.
6
Activities of telithromycin against 13,874 Streptococcus pneumoniae isolates collected between 1999 and 2003.
Antimicrob Agents Chemother. 2004 May;48(5):1882-4. doi: 10.1128/AAC.48.5.1882-1884.2004.
7
Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
J Antimicrob Chemother. 2004 May;53(5):793-6. doi: 10.1093/jac/dkh178. Epub 2004 Mar 31.
8
Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme.
J Antimicrob Chemother. 2003 Dec;52(6):944-52. doi: 10.1093/jac/dkg465. Epub 2003 Oct 29.
9
Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates.
Emerg Infect Dis. 2003 Sep;9(9):1159-62. doi: 10.3201/eid0909.020810.
10
High-level telithromycin resistance in laboratory-generated mutants of Streptococcus pneumoniae.
J Antimicrob Chemother. 2003 Sep;52(3):345-53. doi: 10.1093/jac/dkg348. Epub 2003 Aug 13.
Zotero 插件